Payment overview · 2025
General Payments
$1,858.97
76 reported records · 23 companies
Healthcare provider profile · identity verified
Joel A Pengson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MORENO VALLEY, CA · NPI 1720018237
Verified facts
What the public records show
CMS Open Payments records show Joel A Pengson, MD received $1,858.97 in general payments during 2025 across 76 reported records.
Merck Sharp & Dohme LLC accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Eliquis, Entresto, Farxiga, Jardiance, Kerendia, Mounjaro, Otezla, Ozempic, Trelegy Ellipta, Verquvo, Xifaxan.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $365.91 | 19.7% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $226.67 | 12.2% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $191.97 | 10.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $151.61 | 8.2% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $144.43 | 7.8% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $137.81 | 7.4% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $125.94 | 6.8% | 6 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $83.53 | 4.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $70.96 | 3.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.55 | 2.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.05 | 2.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.75 | 1.8% | 2 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $30.60 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.43 | 1.5% | 2 | 2025 |
| Avanos Medical | Unresolved — no canonical attribution shown | $25.78 | 1.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $22.36 | 1.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.89 | 1.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.14 | 1.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.39 | 1.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.89 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.76 | 1.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.02 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.53 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,858.97 | 76 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $242.28 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $191.97 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $168.23 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $140.79 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $125.94 | 6 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $123.63 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $120.45 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $117.93 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $112.72 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $79.61 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $76.76 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.00 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $70.96 | 3 | 2025 |
Source payment records
|
|||||
| Hillrom - Volara System Normalized: hillrom volara system |
Device | Baxter Healthcare | $56.99 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.55 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $30.60 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $29.35 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.43 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| ON-Q PUMP AND ACCESSORIES Normalized: on q pump and accessories |
Device | Avanos Medical | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 299 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 73 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 61 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 181 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 140 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 150 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
140 | 31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
181 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
181 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
150 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
299 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1174 | 280 |
| Levothyroxine Sodium | Levothyroxine Sodium | 490 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 482 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 481 | 122 |
| Losartan Potassium | Losartan Potassium | 459 | 128 |
| Metoprolol Tartrate | Metoprolol Tartrate | 453 | 106 |
| Gabapentin | Gabapentin | 349 | 85 |
| Metformin Hcl | Metformin Hcl | 347 | 102 |
| Alendronate Sodium | Alendronate Sodium | 318 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 313 | 71 |
| Eliquis | Apixaban | 299 | 49 |
| Lisinopril | Lisinopril | 283 | 65 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 272 | 47 |
| Furosemide | Furosemide | 268 | 66 |
| Levetiracetam | Levetiracetam | 266 | 34 |
| Glipizide | Glipizide | 240 | 62 |
| Donepezil Hcl | Donepezil Hcl | 212 | 44 |
| Famotidine | Famotidine | 206 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 206 | 44 |
| Fenofibrate | Fenofibrate | 205 | 74 |
| Xarelto | Rivaroxaban | 198 | 21 |
| Trazodone Hcl | Trazodone Hcl | 197 | 41 |
| Tramadol Hcl | Tramadol Hcl | 189 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 183 | 56 |
| Jardiance | Empagliflozin | 181 | 46 |
| Carvedilol | Carvedilol | 172 | 40 |
| Memantine Hcl | Memantine Hcl | 165 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 150 | 36 |
| Ozempic | Semaglutide | 150 | 30 |
| Valsartan | Valsartan | 142 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 43 |
| Kerendia | Finerenone | 140 | 31 |
| Clonidine Hcl | Clonidine Hcl | 131 | 52 |
| Omeprazole | Omeprazole | 131 | 38 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 127 | 15 |
| Allopurinol | Allopurinol | 111 | 32 |
| Potassium Chloride | Potassium Chloride | 109 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 30 |
| Mirtazapine | Mirtazapine | 99 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 98 | 34 |
| Simvastatin | Simvastatin | 94 | 14 |
| Vascepa | Icosapent Ethyl | 92 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | 27 |
| Buspirone Hcl | Buspirone Hcl | 85 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 32 |
| Humalog Kwikpen U-100 | Insulin Lispro | 77 | 17 |
| Olanzapine | Olanzapine | 77 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 34 |
| Lactulose | Lactulose | 75 | 28 |
| Megestrol Acetate | Megestrol Acetate | 75 | 30 |
| Entresto | Sacubitril/Valsartan | 73 | 16 |
| Finasteride | Finasteride | 72 | 14 |
| Novolog Flexpen | Insulin Aspart | 72 | 21 |
| Benazepril Hcl | Benazepril Hcl | 71 | 21 |
| Lorazepam | Lorazepam | 69 | 28 |
| Azithromycin | Azithromycin | 68 | 56 |
| Terazosin Hcl | Terazosin Hcl | 67 | 16 |
| Baclofen | Baclofen | 66 | 15 |
| Divalproex Sodium | Divalproex Sodium | 66 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 35 |
| Pregabalin | Pregabalin | 65 | 19 |
| Sucralfate | Sucralfate | 65 | 16 |
| Meloxicam | Meloxicam | 64 | 29 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 15 |
| Folic Acid | Folic Acid | 63 | suppressed |
| Spironolactone | Spironolactone | 63 | 18 |
| Aripiprazole | Aripiprazole | 61 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 61 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 19 |
| Ezetimibe | Ezetimibe | 60 | 21 |
| Alprazolam | Alprazolam | 59 | 16 |
| Humalog | Insulin Lispro | 59 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 59 | 18 |
| Sertraline Hcl | Sertraline Hcl | 58 | 17 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 58 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 57 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 55 | 14 |
| Montelukast Sodium | Montelukast Sodium | 55 | 20 |
| Mounjaro | Tirzepatide | 55 | 15 |
| Azelastine Hcl | Azelastine Hcl | 52 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 37 |
| Lansoprazole | Lansoprazole | 47 | 11 |
| Lidocaine | Lidocaine | 47 | 11 |
| Midodrine Hcl | Midodrine Hcl | 47 | 12 |
| Sodium Chloride | 0.9 % Sodium Chloride | 45 | 19 |
| Mupirocin | Mupirocin | 43 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 35 |
| Icosapent Ethyl | Icosapent Ethyl | 42 | 26 |
| Atenolol | Atenolol | 41 | 11 |
| Carbamazepine | Carbamazepine | 41 | suppressed |
| Adlarity | Donepezil Hcl | 40 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 40 | 20 |
| Myrbetriq | Mirabegron | 39 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Verquvo | Vericiguat | 38 | suppressed |
| Prednisone | Prednisone | 37 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 17 |
| Scopolamine | Scopolamine | 36 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Novolog | Insulin Aspart | 34 | suppressed |
| Otezla | Apremilast | 33 | suppressed |
| Procrit | Epoetin Alfa | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Cephalexin | Cephalexin | 31 | 26 |
| Meclizine Hcl | Meclizine Hcl | 31 | 19 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 30 | 11 |
| Hydrocortisone | Hydrocortisone | 29 | 15 |
| Roflumilast | Roflumilast | 29 | suppressed |
| Xifaxan | Rifaximin | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Acarbose | Acarbose | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Permethrin | Permethrin | 26 | 23 |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 24 | 12 |
| Celecoxib | Celecoxib | 24 | 12 |
| Nitroglycerin | Nitroglycerin | 24 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 23 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 12 |
| Haloperidol | Haloperidol | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Admelog Solostar | Insulin Lispro | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Brilinta | Ticagrelor | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 18 | 14 |
| Glucagon Emergency Kit | Glucagon | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Phenytoin | Phenytoin | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 17 | 12 |
| Novolin R Flexpen | Insulin Regular, Human | 17 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Glucagon Emergency Kit | Glucagon Hcl | 15 | suppressed |
| Valproic Acid | Valproic Acid | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,858.97 · 76 records | Merck Sharp & Dohme LLC | ACCRUFER, AIRSUPRA, AUSTEDO XR, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FARXIGA, FREESTYLE LIBRE 3, Fetroja, Hillrom - Monarch Airway Clearance System, Hillrom - Volara System, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NUCALA, NURTEC ODT, ON-Q PUMP AND ACCESSORIES, OTEZLA, Ohtuvayre, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, TZIELD, VERQUVO, VOQUEZNA, Veozah, WINREVAIR, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error